At the forefront of these innovations are hypomethylating agents (HMAs) combined with venetoclax (VEN) or with IDH inhibitors, either as dual or triplet therapies. Although frontline treatments may involve either HMA + VEN or HMA + IDH-inhibitors, emerging clinical questions press strongly on the comparative efficacy of AZA + VEN versus AZA + IDH-inhibitors versus the triplet HMA + IDH-inhibitor + VEN regimen. Understanding the sequencing and optimal combination of these agents for maximal patient benefit, especially for those with IDH1/2 mutations, remains a high priority, with current trials like the DATA-I (NCT05401097) actively recruiting to elucidate this clinical conundrum.

At the molecular core of these strategies lies the role of IDH mutations in aberrant epigenetic regulation. Wild-type IDH catalyzes the normal conversion of isocitrate to alfa-ketoglutarate (α-KG), vital for DNA methylation homeostasis. However, mutant IDH enzymes aberrantly generate 2-hydroxy-glutarate (2-HG), a potent oncometabolite that disrupts normal epigenetic marks, causing DNA hypermethylation and subsequent blockade of myeloid cell differentiation. Therapeutic inhibition of mutant IDH restores physiological methylation patterns, thereby alleviating differentiation arrest and promoting leukemic cell maturation.

Building upon this mechanistic insight, triplet regimens that incorporate venetoclax, hypomethylating agents, and IDH inhibitors synergistically induce DNA hypomethylation, normalize methylation patterns, and simultaneously trigger apoptotic pathways. This multi-pronged attack not only counters leukemic cell survival but also reverts the epigenetic landscape to a state conducive to normal differentiation and immune recognition, marking a sophisticated evolution in targeted therapy.

Pioneering clinical evidence emerged from the phase 1/2 trial NCT03471260, which evaluated the triplet of ivosidenib (an IDH1 inhibitor), venetoclax, and azacitidine in newly diagnosed AML patients. This combination demonstrated an encouraging trend toward improved progression-free survival (PFS), with median PFS not reached compared to 11 months in control groups. Although differences in measurable residual disease (MRD)-negative complete remission (CR) rates and overall survival (OS) did not achieve statistical significance, patterns in molecular clearance rates—such as 86% IDH1 clearance—indicate meaningful clinical benefits. Importantly, findings suggest that MRD assessment at later treatment cycles might better predict long-term outcomes, a revelation that could refine monitoring paradigms.

The complexity of AML mutational landscapes further complicates therapeutic response, as mutations in FLT3-TKD, RAS pathways (N/KRAS), NF1, PTPN11, JAK/STAT, KIT, and CSF3R genes correlate with inferior prognosis. Notwithstanding these challenges, the incremental improvement in MRD-negativity rates with successive treatment cycles underscores the dynamic therapeutic window these regimens offer. Future investigations will be critical to delineate how such co-mutations influence treatment stratification and resistance mechanisms.

Enasidenib, targeting mutant IDH2, adds another compelling dimension when combined with venetoclax. A phase study (NCT04092179) conducted on relapsed/refractory (R/R) AML patients revealed an overall response rate (ORR) of 70%, with median OS reaching 9.4 months. Notably, patients carrying the R172 IDH2 mutation fared better than those with the R140 variant, exhibiting ORRs of 83% versus 55%, respectively. These insights into mutation-specific efficacy may soon guide individualized therapeutic decision-making, maximizing benefit and mitigating unnecessary toxicity.

Moving toward wholly oral regimens, trials such as NCT04774393 combine ASTX727 (oral hypomethylating agents) with venetoclax and IDH inhibitors like ivosidenib or enasidenib in patients unfit for intensive chemotherapy. Early results herald impressive efficacy, with MRD-negativity rates reaching 91% in newly diagnosed and 67% in relapsed/refractory subgroups by flow cytometry metrics. Such advances promise enhanced patient convenience, improved adherence, and potentially better quality of life during prolonged AML management.

Comparative analyses pooling data from triplets involving ivosidenib + VEN + AZA versus all-oral triplets reveal comparable outcomes and safety profiles, suggesting oral regimens could indeed supplant injectable therapies without compromising efficacy. This evolution could be especially transformative for elderly or frail patients, for whom hospital visits and parenteral administration pose significant barriers.

Looking ahead, next-generation IDH inhibitors, both selective and dual-targeting agents like olutasidenib and crelosidenib, are under active investigation in phase 1/2 trials (NCT06445959 and NCT04603001) for relapsed/refractory IDH-mutated AML patients ineligible for intensive chemotherapy. These novel agents may offer enhanced potency, improved tolerability, and broader mutation coverage, expanding the therapeutic arsenal against this aggressive malignancy.

The real promise of combining venetoclax with epigenetic modifiers and IDH inhibitors lies in its ability to induce durable remissions without relying on traditional cytotoxic chemotherapy’s toxic side effects. By exploiting vulnerabilities in the leukemic epigenome and apoptotic machinery, clinicians aspire to convert AML into a manageable chronic condition with long-lasting remission periods and minimal collateral damage.

Moreover, MRD negativity, increasingly recognized as a surrogate marker for durable responses, gains renewed significance in the context of these targeted regimens. The observation that delayed MRD negativity does not equate to poor outcomes suggests rethinking MRD kinetics and timing to enhance prognostic accuracy and inform therapeutic adjustments.

The intricate interplay of mutational profiles influencing response, resistance, and relapse risk underscores the necessity of comprehensive molecular profiling before treatment initiation. Precision medicine in AML, informed by deep genomic insights, stands at the cusp of delivering truly individualized, chemotherapy-free regimens that optimize efficacy while minimizing toxicity.

In summary, chemotherapy-free combinations incorporating venetoclax and targeted agents represent a vibrant frontier in AML therapy, particularly for vulnerable elderly or unfit populations with IDH mutations. While promising early-phase results signal improved survival and remission durability, ongoing randomized trials and extended follow-up are essential to conclusively establish these combinations as new standard-of-care options. The collaborative synergy of epigenetic modulation, apoptotic priming, and metabolic normalization foretells a paradigm shift that may very well redefine AML management in the coming years.

The rapid accrual of evidence supporting oral formulations further bolsters the case for outpatient, patient-centric care models, reducing healthcare burden while maintaining or enhancing clinical outcomes. As new IDH inhibitors advance through clinical development, they will potentially complement or supplant existing options, deepening therapeutic impact.

Ultimately, the comprehensive approach targeting epigenetic dysregulation, metabolic anomalies, and apoptotic pathways paves the way for sustained remission and improved quality of life in acute myeloid leukemia, offering hope to patients previously facing limited options. The oncology community eagerly anticipates results from ongoing and future trials that will refine and solidify this chemotherapy-free revolution.

Subject of Research:
Chemotherapy-free management strategies for acute myeloid leukemia (AML) using venetoclax in combination with targeted epigenetic and immune therapies, focusing on IDH-mutated patients unfit for intensive chemotherapy.

Article Title:
Comprehensive view on chemotherapy-free management of acute myeloid leukemia by using venetoclax in combination with targeted and/or immune therapies.

Article References:
Kegyes, D., Tat, A., Vizitiu, A.S. et al. Comprehensive view on chemotherapy-free management of acute myeloid leukemia by using venetoclax in combination with targeted and/or immune therapies. Cell Death Discov. 11, 379 (2025). https://doi.org/10.1038/s41420-025-02678-4

Image Credits:
AI Generated

DOI:
https://doi.org/10.1038/s41420-025-02678-4

Acute myeloid leukemia, a malignant hematologic disorder characterized by the rapid proliferation of abnormal myeloid cells, demands early and intensive treatment strategies. The classical mainstay has been induction chemotherapy, aiming to induce a complete remission by eradicating leukemic blasts. However, the substantial toxicity and often dismal outcomes, especially among older patients or those with adverse genetic markers, have led to the exploration of reduced-intensity regimens. VEN-HMAs, which leverage the apoptosis-inducing properties of Venetoclax alongside epigenetic modifiers, emerge as a promising alternative, but their clinical benefit relative to IC has remained ambiguous until now.

The meta-analysis undertook a rigorous search across leading biomedical databases—PubMed, Embase, Cochrane Library, and Web of Science—up to June 17, 2024. Including fifteen retrospective cohort studies that collectively involved 3,809 patients, the researchers applied stringent quality metrics via the Newcastle–Ottawa Scale to ensure the integrity of pooled data. The analytical framework employed random-effects modeling to robustly account for heterogeneity among studies, focusing on critical endpoints including complete remission rates, overall response, short-term mortality, and, most importantly, overall survival (OS).

Contrary to expectations that VEN-HMAs might substantially outperform induction chemotherapy in initial response rates, the analysis revealed no statistically significant differences for complete response (CR) or the combined endpoint of CR with incomplete blood count recovery (CRi). The risk ratios hovered near unity, suggesting equivalence in achieving remission between the two therapeutic approaches. Similarly, the overall response rate (ORR) and 30-day mortality did not differ appreciably, underscoring that the safety profile of VEN-HMAs does not compromise early treatment outcomes.

Where VEN-HMAs demonstrated a compelling advantage was in the domain of overall survival. The hazard ratio of 0.80 indicated a 20% relative reduction in mortality risk compared to induction chemotherapy among the broad cohort of newly diagnosed AML patients. This survival benefit was particularly pronounced in the subgroup harboring nucleophosmin 1 (NPM1) mutations, a genetic aberration frequently associated with better treatment responsiveness and prognosis. In this subset, VEN-HMAs reduced the risk of death by 36%, suggesting a tailored therapeutic niche where the regimen’s mechanism of action aligns with molecular disease drivers.

However, the interplay between VEN-HMA efficacy and cytogenetic abnormalities proved more nuanced. Patients with RUNX1::RUNX1T1 translocations, a relatively rare but defined AML subset, paradoxically exhibited a lower overall response rate with VEN-HMAs, though survival outcomes were not significantly altered. This finding underscores the heterogeneity of AML and the imperative for genotype-guided therapeutic decisions. Notably, due to the limited number of studies focusing on this subset, firm conclusions remain premature and warrant further investigation.

Age, cytogenetic risk categories, and AML subtype – whether de novo, secondary, or therapy-related – did not materially modify the observed survival benefits, suggesting that VEN-HMAs may offer comparable advantages across diverse clinical contexts. This universality hints at the potential for VEN-HMAs to become an integral component of first-line AML treatment paradigms, particularly for patients who are deemed unsuitable for intensive chemotherapy due to comorbidities or advanced age.

The mechanism underpinning Venetoclax’s efficacy rests on its inhibition of the B-cell lymphoma 2 (BCL-2) protein, a critical regulator of apoptosis that is frequently overexpressed in leukemic cells. By restoring apoptotic pathways, Venetoclax sensitizes malignant cells to death signals. When combined with hypomethylating agents such as azacitidine or decitabine, which reverse epigenetic silencing and promote reactivation of tumor suppressor genes, this regimen exerts a multifaceted attack on leukemic cell survival. This synergy likely contributes to the observed extension in overall survival despite similar remission rates.

Importantly, this meta-analysis brings to the foreground the pressing need for head-to-head randomized controlled trials (RCTs) to definitively delineate the relative merits and long-term benefits of VEN-HMAs versus induction chemotherapy. Retrospective cohorts, while invaluable, carry inherent limitations including potential selection biases and variability in treatment protocols. Prospective RCTs could rigorously assess not only efficacy but also quality of life, toxicity profiles, and economic considerations crucial for patient-centered care.

The study’s registration with PROSPERO in July 2024 attests to its methodological transparency and adherence to contemporary standards in systematic reviews and meta-analyses. By preregistering their protocol, the authors reinforced the credibility of their findings and minimized biases that often confound retrospective syntheses.

From a clinical standpoint, these results may inform personalized therapeutic strategies, particularly emphasizing molecular diagnostics to stratify patients likely to derive maximal benefit from VEN-HMA regimens. NPM1 mutation status could emerge as a key decision-making biomarker, guiding clinicians in selecting treatment modalities that optimize survival while balancing risks.

Beyond survival metrics, the equivalence in early response and mortality rates between VEN-HMAs and induction chemotherapy offers reassurance that less intensive regimens do not compromise immediate treatment success. This is a significant consideration given the high toxicity burden traditionally associated with induction chemotherapy, which often limits its applicability among vulnerable patient populations.

The advent of Venetoclax combined with hypomethylating agents thus represents a potential paradigm shift in the management of newly diagnosed AML patients. By integrating targeted apoptotic induction with epigenetic modulation, these agents collectively address the biological complexity of AML while sparing patients the ravages of conventional chemotherapy’s side effects.

Nevertheless, caution is warranted in interpreting these findings. The heterogeneity of included studies, variability in follow-up durations, and retrospective design highlight the necessity for confirmatory evidence from well-designed clinical trials. Moreover, the impact on long-term survivorship, relapse rates, and secondary malignancies remains to be fully elucidated.

In summary, this comprehensive meta-analysis underscores that VEN-HMAs constitute a promising and at least equivalent alternative to induction chemotherapy in newly diagnosed AML, with a notable survival advantage in patients bearing NPM1 mutations. The findings provide a persuasive impetus for ongoing research and clinical trials aimed at optimizing AML treatment algorithms, moving toward a more personalized and tolerable therapeutic future.

As the oncology community eagerly awaits further robust clinical data, these insights offer hope for improved survival and quality of life in a disease that has historically been refractory to treatment innovations. Venetoclax in combination with hypomethylating agents may well be the harbinger of a new era in AML therapeutics.

—

Subject of Research: Evaluation of Venetoclax combined with hypomethylating agents versus induction chemotherapy in newly diagnosed acute myeloid leukemia patients through systematic review and meta-analysis.

Article Title: Venetoclax and hypomethylating agents versus induction chemotherapy for newly diagnosed acute myeloid leukemia patients: a systematic review and meta-analysis

Article References: Liu, Y., Zhang, Y., Gao, J. et al. Venetoclax and hypomethylating agents versus induction chemotherapy for newly diagnosed acute myeloid leukemia patients: a systematic review and meta-analysis. BMC Cancer 25, 894 (2025). https://doi.org/10.1186/s12885-025-14311-9

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14311-9